RPOWER Q4 FY26 Results Analysis: EBITDA Margin Expands 322 bps, Normalized PAT Turns Positive

CompoundingAI Research Updated May 21, 2026 2 min read
Negative

RPOWER's Q4 FY26 numbers came in soft, with revenue of Rs. 1,887.26 Cr (-4.59% YoY) and PAT growth of -493.65% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 21, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 1,887.26 Cr (-4.59% YoY)
PAT (Q4)Rs. -494.00 Cr (-493.65% YoY)
EBITDA margin30.50% (+73 bps YoY)
EPS (Q4)Rs. -1.19 (-481.15% YoY)
Market capRs. 11,286.54 Cr
CMPRs. 27.28

Quarter Snapshot

RPower reported a Q4 FY26 net loss of Rs.494 Cr after a Rs.382 Cr impairment at its RSTEPL subsidiary. However, normalized operating performance improved significantly - EBITDA margin expanded 322 bps to 31% for FY26 and normalized PAT turned positive at Rs.45 Cr vs a loss of Rs.283 Cr in FY25. Cash generation remained strong with CFO at 1.20x EBITDA. Near-term overhangs include the SMPL guarantee invocation (IBC petition filed), ongoing SEBI forensic audit, and ED proceedings. Liquidity remains stressed with Current Ratio at 0.14.

Key Investment Insights

Key Positives

  • Normalized PAT turned positive at Rs.45 Cr in FY26 vs loss of Rs.283 Cr in FY25
  • EBITDA margin expanded 322 bps to 31.0% for FY26
  • Operating cash flow strong at Rs.2,824 Cr (1.20x EBITDA)
  • Free cash flow of Rs.2,708 Cr generated, up 29.5% YoY
  • Debt-to-equity ratio improved to 0.42 (standalone)
  • Sasan UMPP maintained industry-leading 90.6% PLF for 4 consecutive years

Risk Factors

  • Rs.382 Cr impairment at RSTEPL due to technology failure
  • Q4 FY26 net loss of Rs.494 Cr after impairment
  • Current Ratio critically low at 0.14 indicating liquidity stress
  • SMPL guarantee invoked, IBC petition filed by US Exim Bank
  • SEBI forensic audit and ED proceedings ongoing
  • 34.32 crore warrants lapsed, Rs.3,026 Cr forfeited
Share on X · LinkedIn

Disclaimer: This is an AI-generated analysis based on public filings. It is not investment advice, not a recommendation to buy/sell/hold any security, and is not prepared by a SEBI-registered Research Analyst or Investment Adviser.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now